Our Focus
Newormics offers high-throughput and high-content screening devices for small model animals and 3D tissue organoids.
Newormics customers include
OUR TEAM
We are a team of innovators from UT Austin in the fields of microfluidics, imaging, and automation.
Adela Ben-Yakar, PhD.
Chief Executive Officer, Co-Founder
Evan Hegarty
Director of Manufacturing, Co-Founder
Latest news
Newormics at the 2019 International C. elegans Conference
Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June – 24th June. Come and meet the team here at our booth.
Introducing the Next Generation Drug Discovery Platforms
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as 3D tissue organoids. The company provides microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions. Newormics is co-founded by Prof. Adela Read more about Introducing the Next Generation Drug Discovery Platforms[…]